ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company focusing on rationally designed immunotherapeutics against cancer and persistent viral infections, announced it has been granted a European patent (patent no. EP 2 155 240) for the intradermal administration of synthetic long peptides (SLP®s) based on HPV oncogenes, including its lead compound ISA101. Specifically, the patent was granted for the therapeutic use of intradermally delivered long peptides derived from the E2, E6 and/or E7 proteins of the human papillomavirus (HPV) to treat or prevent HPV-related diseases.
The Dutch Financial Times (FD) reports that BBB Therapeutics (formerly to-BBB) is starting through. Under the lead of founder Pieter Gaillard a group of investors reached an agreement with curator Marc Udink on the basic elements of the deal. The actual deal value was not published. BBB Therapeutics was perceived as promising and developed therapies for the treatment of devastating brain diseases.
Galapagos NV announced that Janssen Pharmaceutica NV and Galapagos have mutually agreed to terminate the inflammation alliance and option agreements between the companies. Galapagos views the molecules emerging from the alliance as strong additions to its growing proprietary pipeline. Among others, all rights to candidate drug GLPG1690, a selective autotaxin inhibitor, return to Galapagos. Galapagos has successfully completed a First-in-Human Phase 1 trial for GLPG1690 and is preparing a Phase 2 clinical trial in idiopathic pulmonary fibrosis (IPF).
The team of the Leiden Bio Science Park foundation is organizing another meeting for HR professionals working at Leiden Bio Science Park on April 2nd. This meeting will cover a number of topics, including what it takes for an employer to become ‘A great place to work’ - as illustrated by Pieter Salverda from DuPont. Also, Yvette Buchele will give a brief overview of Cell Signaling Technologies as a Leiden Bio Science Park company. Room for discussion and drinks is planned.
The Leiden Bio Science Park starters program is there to support science-based starters in their first steps as entrepreneurs. We act as a single point of contact for all kinds of starter topics, either providing support ourselves or setting up direct links to relevant partners. Pragmatism, personal contact and speed are central in our approach.
Want to stay informed of the Economic Agenda Leiden region? Subscribe you to the newsletter of program office Economie071. This office coordinates the implementation of the Agenda in which 13 partners are committed. It involves governments, educational institutions and the entrepreneurs of the Leiden region. Together they work on eight projects to strengthen the economy of the region.
Positive outcome of the PURETHAL® Birch RUSH study results in an approved, accelerated up-dosing regimenPublished : Tuesday, March 10, 2015
ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company focusing on rationally designed immunotherapeutics against cancer and persistent viral infections, today announced that its fully-owned subsidiary ISA Therapeutics B.V. has closed an R&D agreement with Japan-based Shin Nippon Biomedical Laboratories, Ltd. (SNBL) to explore a novel nasal delivery for ISA’s cervical cancer immunotherapeutic.
Tech Tour announced the opening of the call for applications for the Benelux Tech Tour which will take place in Belgium and the Netherlands May 20-21, 2015. The Tech Tour Selection Committee will choose the top 50 Emerging companies and the top 25 Growth companies from across the Benelux region and bring them together with leading European Venture Capital firms that are seeking to invest in the region. Selected Growth companies in the previous 2 editions of the Benelux Tech Tour have successfully raised over €170M in funding. Tech Tour’s partners for the event are iMinds and Startups.be who bring a wealth of experience and credibility to the organizing team.
ISA Pharmaceuticals announces start of first Phase I/II clinical trial of its SLP®-AMPLIVANT® conjugatesPublished : Thursday, February 26, 2015
ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company focusing on rationally designed immunotherapeutics against cancer and persistent viral infections, has announced the start of an investigator-initiated Phase I/II clinical trial of a novel immunotherapeutic based on ISA Pharmaceuticals´ platform technology. The trial will be conducted by the Department of Clinical Oncology at Leiden University Medical Center in The Netherlands. The study will investigate the biological activity and safety of the compound in head and neck cancer patients who tested positive for human papilloma virus type 16 (HPV16). HPV infections, in particular HPV16, are one of the major causes of this type of cancer.
Lugus is the name of the new breeding ground for prospective entrepreneurs in the University of Leiden. In the former Chambre of Commerce site next to the Leiden train station a group of proactive students are working on their startups. In that former Chambre of Commerce building where once plenty of new companies were legally established, entrepreneurship is now flourishing once more.
Galapagos NV, a clinical stage biotechnology company focused on developing novel mode of action medicines, announced that the last patient in the DARWIN 1 trial with filgotinib has completed the 12 week visit. This last patient's 12 week visit triggers the clinical research organization's process of final 12 week data collection from all 599 patients enrolled in the trial, to be followed by database lock and analysis. As this process takes approximately 7 to 8 weeks, Galapagos expects to announce topline results by mid-April 2015.
On the 6th of February 120 students celebrated their graduation of the ‘Leren over Leven’ program in Leiden Bio Science Park. The oncology team of Janssen Biologics introduced an educational high school outreach program for high school students 4 years ago. The goal of this program is to give high school students more insight in the field of oncology (both pharmaceutical and healthcare) and is a connection between the world of school and the world of work.
> Read more in Dutch
The pharmaceutical research community meets on 10 March 2015 for the first Leiden Pharma Science Symposium of 2015. This tri-yearly event has been created to stimulate collaboration and exchange about research ideas within the Leiden Bio
Science Park. It is organized by Prof. Henk-Jan Guchelaar, LUMC, Prof. Adam Cohen and Dr Robert Rissmann, CHDR, Prof. Piet Hein van der Graaf, LACDR, and Dr Saco de Visser, LBSP.
All researchers are welcome!
Therefore, all Technolab Friends and school in and around Leiden can sign up for a free workshop!
We were presented with the great opportunity to link with entrepreneur, MIT guest lecturer and business ambassador Jos Scheffelaar! Jos makes himself available to share insights into the Boston high-tech cluster with us, to answer questions about how to best do business there and to simply link up with him and his network. He will host an info&network session next Monday, Feb 23rd, as of 16.00 in the auditorium of BioPartner1 (J.H. Oortweg 19 Leiden).
The Leiden Bio Science Park newsletter is a free bimonthly email newsletter in English. The newsletter offers general life science news, news from the companies and institutions, a company profile, events and jobs.
click here to subscribe